Aaron Goodman

2 months ago | resjournals.onlinelibrary.wiley.com | Seth Bybee |Aaron Goodman |John Abbott |Alabama Museum

CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. Supporting Information Filename Description syen12672-sup-0001-Supinfo.docxWord 2007 document , 17.4 KB Data S1. Supplemental results and discussion pertaining to the divergence time of Cavilabiata and Libelluloidea, as well as morphological scores from our Maximum Likelihood (ML), Bayesian (BI), and Parsimony based analyses.

Sep 21, 2023 | mdpi.com | Aaron Trando |Phillip Yeung |Aaron Goodman |Anna Ter-Zakarian

1. IntroductionChimeric antigen receptor T-cell (CAR T-cell) therapy has demonstrated groundbreaking success in treating multiple hematologic malignancies. CAR T-cell therapies are currently approved by the US Food and Drug Administration (FDA) for use in a number of diverse hematologic malignancies, from the very first approval of tisagenlecleucel (tisa-cel) for relapsed/refractory (R/R) acute lymphoblastic leukemia to there now being six approved CAR T-cell products [1,2].

Jul 6, 2023 | pubmed.ncbi.nlm.nih.gov | Marini BL |Perissinotti AJ |Bernard L Marini |Aaron Goodman

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software

Jul 3, 2023 | thelancet.com | Bernard L Marini |Aaron Goodman

We read the Viewpoint by Nicholas J Short and Hagop Kantarjian with interest.Although we share enthusiasm for novel agents in the treatment of acute lymphoblastic leukaemia, we caution against abandoning randomised controlled trials (RCTs). Single-arm phase 2 studies establish the activity of novel approaches, but not their efficacy. Without confirmatory RCTs, we will continue to repeat the errors of the past.

Jun 29, 2023 | onlinelibrary.wiley.com | Tomer Meirson |Kelly Koehn |Aaron Goodman |Stijn Hentzen

Abstract Objectives Patients with multiple myeloma (MM) enrolled in randomized control trials (RCTs) discontinue treatment for various reasons; however, no prior study has analyzed reasons for discontinuation. We performed a systematic review of MM RCTs to investigate reasons for treatment discontinuation, imbalances between trial cohorts, and reporting practices. Methods A comprehensive search for RCTs in MM from 2015 to 2021 identified 45 studies meeting inclusion criteria.